HKD 3.58
(-0.56%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 397 Thousand USD | -43.69% |
2022 | 705 Thousand USD | 892.96% |
2021 | 71 Thousand USD | 0.0% |
2020 | - USD | -100.0% |
2019 | 88 Thousand USD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2023 FY | 397 Thousand USD | -43.69% |
2023 Q1 | - HKD | 0.0% |
2023 Q2 | - HKD | 0.0% |
2023 Q3 | - HKD | 0.0% |
2022 FY | 705 Thousand USD | 892.96% |
2022 Q4 | - HKD | 0.0% |
2022 Q3 | - HKD | 0.0% |
2021 Q3 | - USD | 0.0% |
2021 Q4 | - USD | 0.0% |
2021 FY | 71 Thousand USD | 0.0% |
2020 Q4 | - USD | 0.0% |
2020 FY | - USD | -100.0% |
2019 FY | 88 Thousand USD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Uni-Bio Science Group Limited | 484.71 Million HKD | 99.918% |
CK Life Sciences Int'l., (Holdings) Inc. | 5.32 Billion HKD | 99.993% |